B.56 Programme - Prostate Cancer Treatment (ICD-10: C61)
Polish NFZ drug programme B.56 for prostate cancer (ICD-10 C61). Use when helping clinicians with patient qualification, drug selection, dosing, monitoring, or follow-up for mHSPC, nmCRPC, or mCRPC treatment with apalutamide, darolutamide, enzalutamide, olaparib, niraparib+abiraterone, or talazop...
